Primary outcome paper by RIO study team shows new HIV treatment could suppress the HIV virus for months

Meesha Patel, 27 May 2026, Imperial College London RIO trial shows a new HIV treatment (broadly neutralising antibody therapy) enables three quarters of participants to safely control HIV without daily medication Summary A randomised placebo-controlled clinical trial led by Imperial College London has shown that an immune-based treatment called broadly neutralising antibodies (bNAbs) enabled 75% […]

Read More…

Aidsmap interview with Professor John Frater at CROI Conference

Gus Cairns from Aidsmap reported from the CROI conference, Denver 22-25 February 2026 following results showing that half the participants from placebo arm of the RIO HIV cure trial have prolonged viral load remission when given broadly neutralising antibodies. https://www.aidsmap.com/news/mar-2026/half-participants-placebo-arm-hiv-cure-trial-have-prolonged-viral-load-remission-when […]

Read More…

RIO Trial featured by Nature Medicine as one of the clinical trials shaping medicine in 2026

RIO Trial Featured by Nature Medicine as One of the Clinical Trials Shaping Medicine in 2026 We’re thrilled to announce that the RIO clinical trial has been selected by Nature Medicine as one of the “Eleven clinical trials that will shape medicine in 2026.” The feature highlights the most impactful and forward‑looking trials set to […]

Read More…

First findings from RIO study shared by community representative on HIV i-Base

RIO is a randomised (1:1) placebo-controlled study looking at whether participants receiving two LS-bNABs (Arm A) could maintain viral load suppression off-ART during an analytic treatment interruption (ATI), for longer than participants who received a placebo (Arm B). Criteria to restart ART during the ATI included viral load >1000 copies/mL for six weeks or confirmed […]

Read More…

Professor Sarah Fidler presents RIO Trial primary outcome at CROI – promising advances in HIV treatment

RIO Trial Demonstrates Long-Acting Immune-Based Therapy can achieve Sustained HIV Control We are delighted to report promising results of the primary outcome of our RIO Trial, which tested long-acting immune-based therapies for HIV. The study recruited 68 participants across 12 clinical sites in the UK and Denmark, who stopped their antiretroviral treatment and received either […]

Read More…

Dr Ming Lee, RIO Trial Physician, appearance on the STI Podcast, IAS Conference Feedback 2023

After presenting at the 2023 HIV Cure & Immunotherapy Forum held alongside International AIDS Society (IAS) 2023, the 12th IAS Conference on HIV Science, in Brisbane, Dr Ming Lee was invited to appear on the Sexually Transmitted Infections (STI) Podcast. The episode, entitled IAS23 Conference Feedback in Brisbane, Australia in July 2023, discussed some of […]

Read More…

Dr Ming Lee (RIO Trial physician) talk on bNAbs in clinical trials at IAS 2023, Brisbane.

Our RIO Clinical Research Fellow at Imperial College London and Imperial College Healthcare NHS Trust, Dr Ming Lee, was invited to speak at the 2023 HIV Cure & Immunotherapy Forum held alongside International AIDS Society (IAS) 2023, the 12th IAS Conference on HIV Science, in Brisbane, Australia. The talk included an overview of the RIO […]

Read More…